Centessa Pharmaceuticals PLC (CNTA) FinancialsCNTACentessa Pharmaceuticals PLC

Evaluating the bottom line, Centessa Pharmaceuticals PLC maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -57.38%, provide a clear picture of how effectively CNTA converts its operational activities into shareholder value.

In the context of the broader market, CNTA competes directly with industry leaders such as LQDA and RGC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, CNTA's gross margin of N/A stands against LQDA's 93.27% and RGC's N/A. Such benchmarking helps identify whether Centessa Pharmaceuticals PLC is trading at a premium or discount relative to its financial performance.